Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Protagonist Therapeutics, Inc

PTGX

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Last trade $124.41
Day change -$0.42 (-0.34%)
Day range $121.58 – $126.04
Volume 229,903
Market cap $8.15B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$8.15B
Price / earnings
23.81×
Price / book
7.51×
Price / sales
14.77×
EV / sales
13.87×
EV / EBITDA
23.59×

Profitability

Earnings per share
$5.24
Return on assets
29.85%
Return on equity
31.55%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.85×
Quick ratio
19.85×
Cash ratio
8.98×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$111.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PTGX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$274.41M$213.48M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M
Cost of revenue$1.1M$0$0$0$0$0$0$0
Gross profit$273.31M$213.48M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M
Selling, general and administrative$13.7M$12.65M$13.28M$11.43M$11.13M$10.55M$11.74M$8.95M
Research and development$41.27M$42.06M$46.74M$46.36M$40M$37.04M$35.89M$34.9M
Total operating expenses$54.98M$54.71M$60.02M$57.79M$51.13M$47.59M$47.63M$43.86M
Operating income$218.33M$158.77M-$3.65M-$50.36M-$46.42M-$42.04M-$19.31M$126.78M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$226.57M$165.11M$2.28M-$43.72M-$39.34M-$34.6M-$11.66M$133.66M
Income taxes$6.56M$2.27M-$1.5M$666K$0$172K$0$1.99M
Net income$220.02M$162.85M$3.78M-$44.38M-$39.34M-$34.77M-$11.66M$131.67M
Net income attributable to common shareholders$220.02M$162.85M$3.78M-$44.38M-$39.34M-$34.77M-$11.66M$131.67M
EBITDA$218.74M$158.77M-$3.24M-$49.98M-$46.06M-$42.04M-$19.07M$126.9M
Basic earnings per share$3.32$2.47$0.06-$0.69-$0.62-$0.55-$0.19$2.11
Diluted earnings per share$3.07$2.29$0.05-$0.69-$0.62-$0.55-$0.19$1.79

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?

Johnson & Johnson's stock has rallied over 10% in a month, driven by better-than-expected Q3 2026 earnings and raised full-year guidance. The Innovative Medicine segment shows strong growth with new drug launches offsetting Stelara's patent expiration, but MedTech weakness, generic competition, and ongoing talc litigation remain concerns. Analysts recommend holding the stock for long-term investors despite near-term headwinds.

Zacks Investment Research

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%

Protagonist Therapeutics (PTGX) stock has gained 1.7% over the past four weeks and closed at $130.95. Wall Street analysts have a mean price target of $180.19, suggesting a potential upside of 37.6%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, with three estimates moving higher over the last 30 days and the consensus estimate increasing 30.7%. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

GlobeNewswire Inc.

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

Zacks Investment Research

Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates

Protagonist Therapeutics reported Q3 2026 earnings of $3.07 per share, beating consensus estimates of $2.58 per share, with a significant turnaround from a $0.62 loss per share a year ago. Revenues reached $274.41 million, surpassing estimates by 2.77% and up dramatically from $4.71 million year-over-year. The company received a Zacks Rank #2 (Buy) rating with stock up 64.2% year-to-date versus S&P 500's 12.3% gain.

Zacks Investment Research

Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates

Niagen Bioscience reported a quarterly loss of $0.01 per share, meeting consensus estimates but missing revenue expectations by 9.81% with $27.19 million in quarterly revenues, down from $33.99 million year-over-year. The stock has declined 62.9% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.